Table 4.
Patients With Multiple Concurrent Fusions and Patients With Multiple FTPs Performed
| Diagnosis | Fusions on First Sequencing | Fusions on Second Sequencing | Interval Treatment |
Vital Status | Survival (Months) |
|---|---|---|---|---|---|
| Pilocytic astrocytoma |
KIAA1549::BRAF; MET exon 14 skipping |
n/a | Radiation, resections, and multiple chemotherapy agents | deceased | 506 |
| Glioblastoma, MGMT promoter methylation detected |
NPAS3::TERT;
TRIM24:MET |
n/a | Chemoradiation | deceased | 4 |
| Glioblastoma, MGMT promoter methylation not detected |
ACAP2::PIK3CA;
FGFR3:TACC3 |
n/a | Chemoradiation, Avastin | deceased | 13 |
| Glioblastoma, MGMT promoter methylation not detected |
ST7::MET;
FRS2:GLI1 |
n/a | Chemoradiation | deceased | 18 |
| Glioblastoma, MGMT promoter methylation not detected | FGFR3::BRAP | FGFR3::TACC3 | chemoradiation, lenvatinib (4 months), cyberknife, pembrolizumab (6 months), and cyberknife, bevacizumab (2 months) | deceased | 20 |
| Recurrent/residual glioblastoma | FGFR3::TACC3 | FGFR3::TACC3 | chemoradiation, second resection with carmustine implant, bevacizumab (16 months), third resection, re-irradiation, pembrolizumab (4 months), and fourth resection, lenvatinib (7 months) | deceased | 41 |
| Glioblastoma | ST7::MET | None detected | Chemoradiation, second resection | deceased | 3 |